EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary
May 18, 2020
Earnings Call Speaker Segments
Operator
operatorGood afternoon. The corporate conference operator speaking. Welcome, and thank you for being with us on the conference call covering EL.En.'s financial results for the first quarter of 2020. Please note that everyone participating is in listen-only mode. Once the presentation concludes, there will be a chance for you to ask questions. If anyone requires help at any point during this call, you can signal an operator by pressing Star and Zero on your telephone. At this moment, I'd like to hand the conference over to Ms. Bianca Fersini Mastelloni of Polytems S.p.A. Please go ahead, madam.
Bianca Fersini-Mastelloni
unknownGood afternoon, or good morning, everyone, and thanks for being with us today. Joining me are Andrea Cangioli, EL.En.'s Managing Director, and Enrico Romagnoli, EL.En.'s Chief Financial Officer and Investor Relator. Before we start, please be aware that management will make remarks on this conference call regarding future expectations, plans and prospects, as well as forward-looking statements. Some of the statements on this call — including those that address the company's beliefs, plans, objectives, estimates or expectations about possible future results or events — are forward-looking statements. Such forward-looking statements carry known or unknown risks, among them general economic and business conditions and conditions in the industry where we operate, and they may be affected if our assumptions prove inaccurate. As a result, no forward-looking statement can be guaranteed, and actual future results, performance or achievements could differ materially from what those forward-looking statements express or imply. The company assumes no obligation regarding the contents, nor to update the forward-looking statements to reflect events or circumstances that may arise after today's date. I'll now hand the call over to Andrea Cangioli. Please go ahead, Andrea.
Andrea Cangioli
executiveThanks, Bianca. Hello everyone, and good afternoon. Appreciate you all joining us on this call following the release of our Q1 2020 financials. To be candid, this is an unprecedented situation we're in. Our operations and our markets have been deeply affected by the COVID-19 pandemic. For the time being, we find ourselves in a rather awkward spot where the past months aren't necessarily a dependable reference point for what lies ahead. On top of that, our current status is probably very different from where we'll be in a few weeks, even though we have only vague ideas about what the new normal might look like. That said, let's begin with comments on our first quarter financials. Once Enrico has given us the detailed introduction, I'll provide more color on the reasons behind the Q1 performance as well as on where our operations and business currently stand. Thank you, Enrico. Please go ahead with your comments on the Q1 financials.
Enrico Romagnoli
executiveThank you, Andrea. Good morning, everyone. As usual, I'll walk you through some details on our financials. The first quarters of 2020 ended with consolidated turnover of EUR 73 million, a 13% decline versus the first quarter of last year. Gross margin came in at EUR 31.5 million, down 5.2% from EUR 33.2 million in March 2019, as a result of the lower turnover. Its impact on turnover, though, rose from 39% to 43% at March 2020, and that increase stems mainly from shifts in the sales mix, with a decline in turnover in the industrial sector, which carries a lower margin than the medical one. It should also be noted that income booked in China for grants tied to R&D activities in the quarter was higher than usual, amounting to 0.7% of turnover. Operating costs were EUR 8.8 million, lower than the EUR 9.9 million of March 2019, although their incidence on turnover stayed almost flat, at around 12%. The savings come mainly from restricted travel and the cancellation of all fair and congress events, as well as from the reduced volume of activities. Staff cost of EUR 15.7 million is probably unchanged compared to March 2019, with its incidence on turnover climbing from 15.7% to 21.5% at March 2020.
Enrico Romagnoli
executiveThe decrease in labor cost stemming from government income support programs—like the implementation of Cassa Integrazione in Italy—is going to matter a great deal in the second quarter, whereas during the first one those measures had only a very limited effect. EBITDA came in at EUR 7.1 million, a decline of 7.8% from the EUR 7.7 million recorded in the first quarter of 2019. That represented a 9.7% impact on sales. Amortization and other accruals rose in line with the significant investment made during 2019, and the provision for bad debt also went up relative to the first quarter of 2019, so as to reflect in the most balanced manner the potential deterioration of certain credit exposures. During Q1, although fixed costs in total declined as a share of revenue, their impact on sales climbed from 33% to 37%. Consequently, EBIT fell from EUR 5.7 million to EUR 4.5 million, equating to a 6.2% impact on sales. The tax result stood at EUR 4.7 million, helped by a positive Forex effect and hurt by a negative contribution from associated companies. Regarding our net financial position, the balance was positive at EUR 27.4 million versus EUR 61.4 million a year earlier. Roughly EUR 20 million in cash went toward acquiring a significant minority stake in Penta Laser Wenzhou during January.
Enrico Romagnoli
executiveNet working capital went up, which absorbed roughly EUR 18.5 million in liquidity, largely because inventory values rose. Fixed asset investment came to about EUR 3.2 million, lower than in the first quarter of 2019. Spending on expanding production structures is indeed below prior years, as most of the new structures are finished or nearing completion. Overall turnover fell 15%, as the medical sector grew 7% while the industrial sector contracted sharply. We see double-digit growth in the aesthetic and service segment, a notable result under the circumstances. In beauty, we performed excellently in the Japanese market, one of the markets least hit by the COVID effect during the first three months. Physiotherapy is down, struck early by the demand decline, whereas the surgery segment holds steady. The service side kept a growth rate above 10%, helped by the full risk maintenance contract, an upgrade sold in the Japanese market, and by optical fiber sales for urological use. Industrial sector turnover shows a 43% overall decline, with contraction of between 30% and 50% across all the main segments.
Enrico Romagnoli
executiveBroadly speaking, how much revenue fell during the quarter tracks with how long each activity was down. The decline was bigger in the cutting sector, which had a halt in China and afterwards in Italy, while it stayed comparatively more limited in the other segment, whose activities outside China stopped for March only. Turning to how revenue is spread across geographic areas, COVID-19 essentially shut down sales in China for over two months. That explains the sales decline in the industrial sector outside Europe. The sales drop in Italy is significant, since the medical and industrial market there was entirely blocked in March. The European area, by contrast, posted excellent growth, with the trend matching the pre-COVID-19 forecast, because deliveries to distributors were possible through the end of March, even though lockdowns in Europe took effect in April. Andrea, please go ahead.
Andrea Cangioli
executiveThanks a lot, Enrico. All right. What the Q1 financials tell us is essentially that our industrial business had a terrible quarter while our medical business had a strong one. Because our operations are fairly diversified across regions and market segments, we have to dig into more granular detail to get a clearer sense of what really took place, and to form a view of what's going on right now and what might unfold over the coming months. To start with, when the opening days of the year arrived, 2019 had just wrapped up with record results across the board, with growth and earnings beating expectations, and the sole business that had slowed during the second half of 2019 was laser metal cutting in China. On the very first day of 2020, order bookings looked excellent across every one of our businesses, from surgical to aesthetic, from Brazil to the U.S. In China, they were quite strong, in line with the growth we had projected for the year. As you know, we are counting on growth in our Chinese industrial business — so much so that we chose to buy out our main minority shareholder to sharpen our capacity to grow in that market.
Andrea Cangioli
executiveBy the way, this involved a EUR 20 million investment that, rather ironically given how this month looks in the short term, was wired to China on January 16th under the purchase agreement, right as the 2020 Spring Festival break began — which ultimately became an extremely, extremely lengthy break for China. Back then, the word "lockdown" had not yet come into common use. Pardon me, but Wuhan was placed under a very strict one, and afterward other cities where the virus had spread were likewise subjected to harsh restrictions. Because movement was restricted inside China, all three of our plants — located in Wuhan, Wenzhou, and Linyi — were closed. The majority of our staff had to remain at home for a very extended period. Since our commercial footprint in China began in Wuhan, and over the past years we relocated workers from Wuhan to Wenzhou and Linyi, the Spring Festival left most of our people stranded in Wuhan, the center of the epidemic. Only one employee was infected, thank God, and that person recovered shortly afterward. We had to endure a very prolonged suspension of our operations and of our sales efforts. The plants in Wenzhou and Linyi stayed down for more than a month. Once Wenzhou and Linyi were able to resume activity after mid-February, just a small number of staff could actually work, since several of them were confined in Wuhan, where restrictions were only eased toward the end of March.
Andrea Cangioli
executiveThat explains why our revenue fell 70% quarter-over-quarter in Q1 2020 — a steeper decline than what China saw on average. When the pandemic began shifting toward the West, Italy was the first nation hit hard. Our industrial laser business, particularly laser metal cutting, had been enjoying a record quarter. The restrictions struck that business right from the outset, because they banned business travel outright. As a result, we couldn't finish installing a number of systems we had already shipped to customers across the country. Our customers were deeply frustrated as well — they badly needed those systems to meet their rising demand. They had to delay the purchase, yet not one purchase order was cancelled. As the restrictions grew even stricter near the end of March, production had to halt entirely. The net impact on Cutlite Penta, the Italian company running the laser cutting business, was a 3% revenue decline versus Q1 2019 — which tells you everything about what that quarter might have looked like under normal circumstances. Other segments of our industrial sector saw a slowdown starting in March, as demand weakened, order intake volumes shrank, and customers asked to postpone deliveries.
Andrea Cangioli
executiveOn the pandemic side — and I'm still on our industrial business here — it eventually hit Brazil, and that led to several orders for the laser cutting system we had in-house being suspended, which cooled off the strong recovery trend that had started in 2019. Our medical business was a completely different story. To begin with, our revenue presence in China isn't as large as it is in the industrial business. So at the outset we felt almost no impact from the Chinese lockdown. Business was excellent through the two full months of January and February. When the pandemic struck Europe and Italy, the effect varied by area and by distribution channel. In places where we run direct distribution, the lockdown effects were immediate and drastic. The medical aesthetic network in Italy, Renaissance by DEKA, the professional aesthetic business network in Italy, Esthelogue, and the medical aesthetic distribution in France were halted on the very first day of March. Distribution in medical aesthetics in Germany slowed down materially. Meanwhile, our worldwide distributors kept demand at a very strong level. As a result, our factories were able to run full time and full throttle for our export customers. Only our Quanta System plant in Lombardy, right in the center of the Italian pandemic, chose voluntarily to halt production for two weeks to protect its workers and their families.
Andrea Cangioli
executiveThe global drop in demand only became apparent in the latter part of March, when the pandemic compelled every other Western nation to go into lockdown—including, finally and crucially for us, the U.S.A. That falloff in demand meant customers asked us to hold off on delivering orders already booked; we did not record a single cancellation, yet order intake during this stretch has been extremely sluggish. COVID-19 touched our direct distribution in Japan only very slightly in Q1, because the central government's mild restrictions in certain areas did not actually come into force until April. Turning lastly to the different market segments, the surgical one proves the most resilient—urology in particular, which by its very nature has suffered less than medical aesthetic was struck by the pandemic. Through the lockdown stretches, law and the collapse in demand alike compelled us to shut or scale back operations at our plants. We let staff work remotely from home—what in Italy is now termed smart working—which for some activities was genuinely smart. I refer to sales and marketing: with travel prohibited, we drew on web marketing's capabilities—web TV and webinars—as never before, capturing the attention of hundreds of customers and prospective customers.
Andrea Cangioli
executiveBecause the conferences and trade shows we normally use were called off, we introduced new products online and ran training webinars covering a number of topics tied to our system. Our take is that this went really well, and going forward this type of web marketing will make up a bigger share of what we offer. The short-term P&L gains from the travel ban and the cancellation of conferences — particularly in medical aesthetics, where such sales and marketing expenses account for a sizable portion of our costs — were notable. Naturally, those P&L benefits are short-lived, because we will lose the gains on order booking sales, on order bookings, and on sales that our customary extensive marketing activity would bring. As I mentioned, we could also look at a broader web-based approach with reduced travel down the road. The factories that stayed up and running during this phase have above all adjusted how work is organized so as to safeguard health and ensure our employees' safety. Every protective measure the authorities asked for has been adopted proactively. Temperature checks on entry to the buildings, capped office attendance to ensure minimal distance, remote working as I mentioned, ongoing cleaning, and full sanitization whenever necessary.
Andrea Cangioli
executiveTo cut costs and keep cash on hand, we had no choice but to bring in what's known as the salary integration fund, Cassa Integrazione, across every one of our factories in Italy, in France, and to some degree in Germany as well. Our employees have behaved outstandingly. I want to express my thanks to them for their dedication, their tenacity, and their patience as well during this critical situation. Before I give you an overview of where our business stands right now, a quick note on the cash management front. We believe our group is strong enough to get through this downturn. A downturn this sudden and this widespread will hit our profits, and it has already hit net working capital, because all of our manufacturing facilities had been set up and were prepared to support a higher level of production in the months ahead. Inventory levels stood high at the close of March, and that is bringing forward the cash outflows for raw material purchases that we will need to carry for some period until production and sales levels soak up that excess inventory once more. From that standpoint, of the EUR 18.5 million rise in net working capital during the period, EUR 11 million is tied to the Chinese company in the metal laser cutting business.
Andrea Cangioli
executiveSince the pandemic wave struck our worldwide business at varying moments and in varying manners, we now face a range of differing circumstances as restrictions get lifted over time. First, let's look at how things are going where it all began, in China. The impact there was sharp and tough, but the good news is that recovery seems strong. What must be kept in mind is that the virus hit hard in only a small portion of China — a relatively marginal area for China's economy, if you will. Unfortunately, the most vital part was hit. As a result, China and its internal markets got back to business relatively easily. In Q1, we had to absorb a heavier impact than competitors based elsewhere in the country. For instance, Han's Laser is based in Shenzhen, and they got the chance to return to work sooner than we did. At present, our order acquisition and production level are back to normal. What I mean is that we saw a gap in the first quarter, but we're doing fine now. It's hard to say whether this gap will persist — whether this revenue and profit gap is simply what we'll be missing at year-end — or whether over the coming months we'll be able to make up for the revenue and profit loss of Q1.
Andrea Cangioli
executiveOverall, the sense is that China is positioned for a faster rebound than the remaining Western nations. In Europe, our laser cutting operation — chiefly the Cutlite Penta business — once it is permitted to resume operations, with production as well as on-site service and installation, appears fairly robust and somewhat resembles what we are observing in China. The market is strong, just as it was 3 months back, prior to the gap emerging. One intriguing consequence of the pandemic is that we gained a handful of orders for plexiglass cutting systems, since adoption of acrylic protection panels and windows is widespread across offices and shops, beauty spas included, to safeguard operators and customers. Along similar lines, O.P.L.A.S. is helping its customers adapt their systems for laser cutting of protective masks — a task carried out very effectively with our laser marking system for large surfaces. Demand for laser marking systems used for identification — the business of LASIT, our company headquartered in Torre Annunziata, near Naples — remains soft during this phase as well. Because of a tighter link between certain customers of ours and the automotive verticals, those customers continue to struggle. To wrap up the industrial marking picture: following the stoppage, demand for mid-power CO2 laser sources looks promising, helped also by the ongoing enhancements our R&D has delivered to our technologies and their broad range of usability.
Andrea Cangioli
executiveBrazil is still a market with a lot of potential in metal cutting, but with the COVID wave having shifted from east to west, the most recent information indicates that the country is still going through a serious stage of pandemic impact. As we have observed, our medical business had a very good Q1. In April and May through today, our direct markets in Italy, France, and Germany remained closed. As a result, direct sales revenues came in at close to zero. Shipments to distributors around the world did take place during this period, but the overall revenue level stayed low. We kept up decent sales volumes with customers in the surgical market and in the Far East, since those areas appear to be getting past the pandemic more effectively. Today marks the reopening day in Italy, after similar milestone days in Europe and with others still to come around the world. It is very hard to predict how market demand will develop. At the micro level of our customer in professional aesthetics and medical aesthetics in Italy, we see a strong wish to return to normal. Our customer, medical doctors, and beauty spas are under pressure from their own clients, who cannot wait to begin getting ready for the return of social life and for summertime body exposure.
Andrea Cangioli
executiveLooking at the broader picture, we have a lot of confidence that our markets will recover. That confidence rests on the long-term growth that determines each of them, and on our own strength and our capacity to seize the demand we expect. Naturally, at this moment we cannot say with any clarity how long it will take for demand to return to where it stood before COVID. We don't know what ordinary life will look like during this transition from the pandemic to normal life, once the pandemic has been overcome or has disappeared. We don't know how the pandemic will reshape our lives into a new normal that could bring significant threats as well as significant opportunities for our business. Throughout this lockdown period, we cut back the volume of our activity, yet we kept every one of our vital functions not merely alive but lively. Research and development, marketing, regulatory — all carried on the preparatory work our organization needs in order to be genuinely positioned to benefit from the recovery, whenever it comes and in whatever form it takes. The scenarios we are able to sketch for the near future remain highly uncertain. As a result, we are not issuing a guidance at this time. We will return to our customary guidance release as soon as the business trend for the coming months is, if not more stable, then at least dependent on business trends rather than on the unprecedented and unpredictable effects of the pandemic.
Andrea Cangioli
executiveI appreciate everyone joining us today.
Operator
operatorPardon me, this is the operator speaking. Is everyone set to begin the question-and-answer portion?
Andrea Cangioli
executiveYeah. I’m finished. We’re finished. Yeah.
Operator
operatorAlright.
Andrea Cangioli
executiveThat brings us to the end.
Operator
operatorWe'll now start the question-and-answer portion. If you'd like to ask something, you can press Star and One on your phone. Should you want to drop out of the queue, just press Star and Two. When you ask your question, please lift the receiver. At this point, anyone with a question can press Star and One. Our first question comes from Francois Billard at Intermonte. Sir, please go ahead.
Francois Billard
analystHello there. Good afternoon to all of you, and thanks for asking my question. To start, I hope everyone is doing well. My first question concerns the higher bad debt you referenced for the first quarter. Could you share additional detail on how that rise in bad debt affected Q1 and how things developed during April and May? Regarding plastic surgery, if I understood correctly, you said there are already some short-term opportunities in Italy. Could you elaborate a bit more? Is it material, and on marginality relative to your normal business, what should we expect from it? That is, if it is material, of course. On the China recovery, if you could return to that point, you said production and order intake are back to normal. In your view, could that be tied to some negative developments ahead, perhaps in international orders, industrial orders going to China? Lastly, on your order book, if you can give us some visibility: you said no order had been canceled. Does that hold true across all of your segments? Thank you very much.
Andrea Cangioli
executiveLet me begin with bad debt. On that front, we're facing a situation that's evolving extremely quickly. Our allowances for bad debt were applied in a more generous manner. They were broader than they had been previously. And we also factored in what might take place over the next few months. Naturally, there are certain sectors where we're hurting, and there are areas where customers, when they request that deliveries be pushed back, at the same time ask for payments to be pushed back. Nothing at this moment can be pinned down precisely. Enrico may be able to walk you through the specifics of the figures, but there's nothing concrete. There are certain markets where we chose to set aside special allowances, namely China and Europe.
Enrico Romagnoli
executiveRegarding that, pardon me.
Andrea Cangioli
executiveNo, Enrico. Sure, please continue.
Enrico Romagnoli
executiveIn Q1 2020, the rise in bad debt versus the first quarter of last year was EUR 0.5 billion, and that difference is what affects the profit and loss.
Andrea Cangioli
executiveDuring Q1, bad debt came to EUR 0.6 million, versus EUR 0.1 million in the first quarter of last year. Naturally, provisions of this type rest on the premise that our operations will continue, and so will those of our customers — a premise we firmly hold to, since if it did not hold, the provision would have been entirely different. The underlying assumption, though, is that we are going through a period of interaction lasting some time, one that will hit us on the P&L, one that will cost us money, but one that will not destroy our work. If that were not so, our provisions would look different. On plastic cutting, we moved a few units — a handful of units, I think. Overall, the impact is not material. What is interesting is that at this stage we managed to sell more of these units than we would ordinarily have done, bearing in mind that of late our selling effort has focused mostly on metal cutting. As for the future in China — I'm sorry, but I can't provide any further details. I devoted a good deal of time to explaining to you what is happening in April and in May, and what we anticipate. No guidance is being issued by us, and so no additional detail can be given to you.
Andrea Cangioli
executiveI can confirm that what we're seeing in China is extremely encouraging when it comes to life returning to normal. That's true somewhat across the board. Restaurants in Shanghai have been open for a long time. People were moving around within the cities quite freely. Also, the one person — the only talent manager we managed to reposition in China, since only one was able to fly, while the others are still in Italy because they can't fly back to China right now — is experiencing a very proactive environment. He's traveling among the various cities of China by plane or by car. It's seen a very strong recovery after these months of halt. That's it for the answers.
Operator
operatorAndrea Bonfà from Banca Akros has the next question. Go right ahead.
Andrea Bonfà
analystHello, and good morning or good afternoon to everyone. Andrea, my question concerns the profitability we should anticipate for Q2. I believe the first quarter came in above what I had expected, and I think the market felt the same way, since the gross margin was also a very pleasant surprise. Given your mix, again, Q2 could turn out the opposite way. If you could perhaps expand on that. My second question is really more qualitative in nature. From where you sit, what are you sensing about how the severity of this pandemic is perceived across the different countries? My own sense, again, is that starting from Italy and from Milan especially, we are getting a situation that is worse than it may actually be, particularly in the aesthetic sector. I'm not sure if that's clear. Just, what are you picking up around the globe from the various markets? From a Milan perspective, I would say that in the aesthetic sector we ought to see a very slow recovery. Perhaps that isn't true in other countries. Your thoughts on this would be helpful. Thank you very much.
Andrea Cangioli
executiveThanks, Andrea. Yes, that's correct. The growth margin in Q1 genuinely caught us off guard on the upside, though really, it follows from the math. The weighting of our higher-margin sales within medical was significantly greater than it had been previously. In addition, on the industrial side, we were lacking the lower-margin portion, meaning the Chinese portion. Medical versus industrial split 60% to 40% in 2019, then 73.3 to 26.7 in 2020. That explains the margin expansion and the strong profitability. In fact, looking at the medical business, profitability there was outstanding, partly because we captured nearly all of the sales revenues across the three months while expenses were lower, since we incurred nothing for congresses or travel. Medical profitability was excellent in Q1. During Q2, we know things will flip entirely, since for China — April, May, and June — we anticipate solid months. On the industrial side, for May and June, we anticipate very strong months. Meanwhile, in medical, we know April and May will be quite slow. As for June, making a projection right now is difficult, since June will depend heavily on how reopening unfolds in the market.
Andrea Cangioli
executiveThat connects your first question with the second one. Yes, I think certain markets are going to bounce back quite quickly, including in aesthetics, since nations that were hit less hard—and that can return to normal daily life sooner, meaning services for individuals, meaning visits to the aesthetician, meaning appointments with medical personnel or the doctor for particular treatments—are going to rebound faster. What you said is accurate. In Italy, we had the feeling that the impact on the aesthetics market might be extremely severe. Now we must wait and see. As of today, in Tuscany at least, aesthetic clinics are opening their doors again. Across most of Italy, they are reopening. I know that women—we see this through our web activity this month—are finding it hard to get back to having treatments done, having their hair styled again, and all of that. I know that demand from the base is extremely strong. Naturally, that alone isn't sufficient for us, because we require confidence to be restored. Our customer needs confidence restored so that they will invest once more. As I say, at the close of the quarter we'll see how many.
Andrea Cangioli
executiveRight now we're delivering systems in Italy—in aesthetics at the moment, during these weeks—and in medical aesthetics as well. We're seeing some demand there. I'm certain the return to normality will be slower than what China experienced on the industrial side, and possibly slower too than what the industrial laser business appears to have shown. The recovery will take longer, but the signals over these very last days aren't all that negative.
Andrea Bonfà
analystMuch appreciated.
Andrea Cangioli
executiveNo problem.
Operator
operatorJust a quick reminder that if you’d like to sign up to ask a question, press star and one on your phone. I’ll say that again: if you want to pose a question, press star and one on your telephone. Should you have any additional questions, press star and one. We now have a follow-up from Arturo Birra at Intermonte. Please go ahead.
Arturo Birra
analystMy apologies—are you able to hear me?
Andrea Cangioli
executiveYes.
Arturo Birra
analystAlright, apologies. Just a brief question regarding labor cost. You brought up Cassa Integrazione in Italy — what sort of fixed cost savings on staff cost should we anticipate for Q2?
Andrea Cangioli
executiveThere are a few reasons I can't give you that answer. The biggest one is that we're 50% of the way through the quarter, and if demand comes back, we'll have everyone working at full force the way we do in industrial. If demand stays steady, we'll need to keep people at home a bit longer. Naturally, this cost reduction only affects the Italian factories. There will be a reduction. Sorry, I don't have that number yet. Naturally, it will be significant if you look at it business by business. Take Esthelogue, for example — that company actually didn't operate for six weeks, so employee cost ought to run about 20% of the normal cost across these first seven weeks of the quarter. In the second half, they'll probably be working full time, because now that the institutions have reopened, we need to support them and make sure we're visible to everyone so we can try to recover on sales and distribution. For the other companies, the cost impact will be much lower, since we keep working and keep producing to some extent. On the whole, I expect a cost reduction, though not a 50% reduction on personnel cost.
Arturo Birra
analystAll right, thanks so much.
Operator
operatorTo repeat, if you'd like to ask something, hit star and one on your phone. Should you have any additional questions, just press star and one on your phone again. Sirs, no further questions have come in at this point.
Andrea Cangioli
executiveThanks to all of you for joining us. Enrico, I think we’ve got a short-term, let’s say, plan for our next meeting, since in roughly 10 days from now the virtual STAR Conference is taking place, right?
Enrico Romagnoli
executiveYes. We'll be at the STAR Conference on May 26 and 27. That's 10 days from now, so we can meet up again then.
Andrea Cangioli
executiveThanks, Bianca, and thanks to all of you. I can't wait to meet you in person — well, virtually — 10 days from now. Bye-bye.
Bianca Fersini-Mastelloni
unknownThanks a lot, everyone. Bye. Bye-bye.
Andrea Cangioli
executiveTake care. Enrico?
Enrico Romagnoli
executiveYes?
Andrea Cangioli
executiveGood. Alright. Everything's in order.
Operator
operatorThanks, everyone, for taking part in today's call — at this point you're welcome to hang up your phones. Thank you.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.